Company Profile / Molecular Diagnostics
3EO Health.
Molecular performance at antigen prices. The Massachusetts company that decided lab-grade testing shouldn't cost more than lunch.
Molecular performance at antigen prices. The Massachusetts company that decided lab-grade testing shouldn't cost more than lunch.
Somewhere in a clinic this morning, a patient swabbed their own nose, dropped the sample into a reusable base unit the size of a paperback, and waited about thirty minutes. No pipettes. No centrifuge. No courier driving a vial to a distant lab. The result that came back was molecular-grade - the kind hospitals used to reserve for expensive machines in back rooms. The test cost under fifteen dollars.
That clinic is running 3EO Health's platform, and the scene it describes is the whole argument. 3EO is a molecular diagnostics company in Beverly, Massachusetts, with around nineteen employees and a single stubborn idea: the choice between accurate and affordable was always a false one. Most of the diagnostics industry treated that tradeoff as a law of physics. 3EO treated it as a pricing problem someone forgot to solve.
"A 'Point of Life' diagnostics company - extending the four walls of the health system into the home, work, and community."
For decades, molecular testing - the gold standard, the PCR that actually finds the pathogen rather than guessing at it - lived behind a price wall. The chemistry demanded sample preparation, costly consumables, trained technicians, and machines that cost as much as a car. Antigen tests were cheap and fast but missed cases. PCR was precise but slow and expensive. Patients, especially the ones with the least access, got whichever the system could afford to give them, which was usually the cheaper, blunter option.
The pandemic made the gap impossible to ignore. Millions of people needed answers that were both correct and quick, and the existing toolkit forced a compromise on one or the other. The market had quietly accepted that good diagnostics were a luxury good. It is a charming assumption, the way most expensive assumptions are.
"Technological advances like at-home testing may enable new models to emerge that have the potential to address inequities in access and care."
The science started at Harvard's Wyss Institute for Biologically Inspired Engineering, in the lab of Peng Yin, a Core Faculty member and professor of systems biology who spends his days bending DNA into machines. Alongside researchers including Thomas Schaus and Nikhil Gopalkrishnan, the group developed an ultrasensitive way to detect nucleic acids - the genetic fingerprints of viruses and bacteria - without the heavy lab apparatus that usually comes attached.
In 2021 they spun it out, took a worldwide exclusive license to the technology, and recruited a commercial operator to run it: Jeremy Schubert, a former Abbott Diagnostics divisional vice president with degrees in both business and public health. The bet was specific. Not "build a better test." Build a test so cheap that the access problem dissolves on its own. Academics are not usually accused of being practical; this group is the exception that proves the rule.
"PCR-level accuracy at antigen-level cost."
At the center is a proprietary amplification method 3EO calls 3TR. Its trick is what it removes. Conventional molecular tests need a sample-preparation step - extracting and purifying genetic material before the chemistry can run. That step is where the cost, the equipment, and the human error all live. 3TR was engineered to work without it.
The result is a system with two parts: a reusable base unit and a small, single-use cartridge specific to the pathogen you are hunting. The workflow strips out mixing, pipetting, and every technique-dependent move that used to require a trained hand. You can hand it to someone who has never set foot in a lab. 3EO calls this category "high efficiency" molecular testing - low-cost, easy to use, under $20 per test, no sample prep. The COVID-19 test was first; respiratory panels and sexually transmitted infections are on the roadmap.
"No mixing, no pipetting, no technique. They designed molecular testing anyone could run - which is harder than it sounds."
Claims are easy in diagnostics. Validation is not. 3EO's COVID-19 test cleared FDA Emergency Use Authorization in late 2023, and in its clinical study it correctly identified 95% of positive samples and 100% of negative samples when measured against an FDA-authorized laboratory molecular test. That is the benchmark that matters - the test held up against the lab-grade standard it was trying to undercut on price.
The validation came with company it could keep. 3EO was selected for the 2023 MedTech Innovator Accelerator, one of 61 startups picked from a much larger field. It received an NIH RADx Tech award to broaden the platform. Reporting places its total funding well past $30 million across venture rounds and non-dilutive awards, with investors including ARCH Venture Partners and S32, plus support tied to federal programs like BARDA. For a nineteen-person company, the signal-to-headcount ratio is unusually high.
3EO is not a random string. The 3 stands for three pillars of wellness - the health system, the community where you live, and the home where you live it. The EO stands for Exceptional Outcomes for EveryOne at the Earliest Opportunity. It is a mission statement disguised as a brand, which is either earnest or clever, and is probably both.
The strategy follows the name. By collapsing the cost of a molecular test, 3EO is trying to move diagnostics out of the centralized lab and into the places where people actually are - the clinic down the street, the workplace, the kitchen table. Cheaper tests mean physicians can order more of them, sooner, and catch what a slower or blunter test would miss. The company's term for this is the "point of life." The less polished version: find the problem early, where the person is, before it gets expensive.
"Exceptional Outcomes for EveryOne at the Earliest Opportunity. They spelled out their own thesis and then put it in the logo."
The hard part of cheap diagnostics is not the first test - it is the second, third, and tenth. A platform that works for COVID-19 has to prove it works for respiratory panels, for sexually transmitted infections, for the long list of things a clinician wants to rule in or out on the spot. That is the test 3EO is taking now. If 3TR holds across that menu, the price floor for molecular testing moves for an entire industry, not just one virus.
So return to that clinic from this morning. A patient swabbed their own nose, used a device the size of a paperback, and got a molecular-grade answer in half an hour for under fifteen dollars. A few years ago that sentence would have required a lab, a courier, a technician, and a bill several times larger. 3EO Health did not invent molecular testing. It removed the wall that kept most people on the wrong side of it - and once a wall is gone, it is remarkably hard to put back.